IMPACT BIOMEDICAL INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for IMPACT BIOMEDICAL INC. (IBO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are IBO insiders buying or selling?
In the last 12 months, IMPACT BIOMEDICAL INC. insiders reported 0 open-market purchases ($0) and 4 sales ($147.5K) — net selling of $147.5K. Since September 2024, Trabud has recorded 17 Form 4 filings for IBO: 5 buys ($160.7K) and 12 sells ($7.5M).
Source: SEC EDGAR Form 4
What stands out
- No IMPACT BIOMEDICAL INC. insider made an open-market purchase in the last 12 months; the 4 reported open-market sales totaled $147.5K.
Key Statistics (September 2024 – Sep 24, 2026)
Total Form 4 filings
17
SEC EDGAR
Insider filers
5
Insider buys (5)
$160.7K
Insider sells (12)
$7.5M
Insider sentiment
Net sellingNet insider flow of $7.3M in net selling since September 2024, and $147.5K in net selling over the last 12 months.
Recent IBO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | DSS, INC. | 10% Owner | Sale | 906 | $1.86 | $1.7K | SEC ↗ |
| Mar 31, 2026 | Todd D Macko | Chief Financial Officer | Sale | 45.0K | $0.56 | $25.3K | SEC ↗ |
| Mar 25, 2026 | Jason Grady | Director | Sale | 50.0K | $0.65 | $32.5K | SEC ↗ |
| Jan 6, 2026 | DSS, INC. | 10% Owner | Sale | 161.0K | $0.55 | $88.0K | SEC ↗ |
| May 27, 2025 | DSS, INC. | 10% Owner | Sale | 161.0K | $0.55 | $88.0K | SEC ↗ |
| Apr 8, 2025 | DSS, INC. | 10% Owner | Sale | 890.8K | $0.95 | $845.0K | SEC ↗ |
| Apr 7, 2025 | Heng Fai Ambrose Chan | Director | Sale | 351.6K | $0.50 | $174.0K | SEC ↗ |
| Apr 4, 2025 | Heng Fai Ambrose Chan | Director, 10% Owner | Sale | 1.7M | $0.66 | $1.1M | SEC ↗ |
| Apr 3, 2025 | Heng Fai Ambrose Chan | Director, 10% Owner | Sale | 2.5M | $1.15 | $2.9M | SEC ↗ |
| Mar 28, 2025 | DSS, INC. | 10% Owner | Sale | 605.6K | $3.22 | $2.0M | SEC ↗ |
| Mar 25, 2025 | DSS, INC. | 10% Owner | Sale | 53.1K | $4.69 | $249.1K | SEC ↗ |
| Dec 9, 2024 | Frank D Heuszel | Chief Executive Officer | Purchase | 500 | $2.26 | $1.1K | SEC ↗ |
| Dec 4, 2024 | Frank D Heuszel | Chief Executive Officer | Purchase | 500 | $2.61 | $1.3K | SEC ↗ |
| Dec 4, 2024 | Frank D Heuszel | Chief Executive Officer | Purchase | 1.1K | $2.61 | $2.7K | SEC ↗ |
| Nov 22, 2024 | DSS, INC. | 10% Owner | Sale | 5.7K | $2.99 | $17.0K | SEC ↗ |
| Sep 19, 2024 | DSS, INC. | 10% Owner | Purchase | 1.0K | $2.33 | $2.3K | SEC ↗ |
| Sep 19, 2024 | DSS, INC. | 10% Owner | Purchase | 57.8K | $2.65 | $153.2K | SEC ↗ |
Showing the 17 most recent of 17 Form 4 filings for IMPACT BIOMEDICAL INC..
Most active IBO insiders
- DSS, INC.9 filings
- Frank D Heuszel3 filings
- Heng Fai Ambrose Chan3 filings
- Jason Grady1 filing
- Todd D Macko1 filing
Ask anything about IBO insider activity
Use Trabud's AI agent to query IMPACT BIOMEDICAL INC.'s Form 4 history in plain English — "Show me IBO CEO purchases this year" or compare it against any other ticker.
Open the AI agentIBO insider trading FAQ
Are IMPACT BIOMEDICAL INC. insiders buying or selling?
In the last 12 months, IMPACT BIOMEDICAL INC. insiders reported 0 open-market purchases ($0) and 4 sales ($147.5K) — net selling of $147.5K. Since September 2024, Trabud has recorded 17 Form 4 filings for IBO: 5 buys ($160.7K) and 12 sells ($7.5M). Over the full record that is net selling of $7.3M.
How many insiders trade IBO stock?
5 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for IMPACT BIOMEDICAL INC.. The most recent filing was accepted on Sep 24, 2026.
Where does Trabud get IBO insider trading data?
All IBO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.